MARKET WIREYahoo! Finance Canada • 8h ago
IQVIA Holdings Inc. (IQV) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
Why IQV Stock dropped -2.81% Today — RQD Quant Desk Flash
$267.33 -2.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $265.47
IQVIA Holdings Inc. (IQV) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $45.33B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IQV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, IQVIA Holdings Inc. (NYSE: IQV) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $267.33 (-2.81% 1D, market cap $45.33B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IQV ranks #132 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IQV compare to INCY and MEDP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C (64/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A- grade (84/100 RQD, P/E 18.4x, ROIC 42.4%, cap $23.68B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IQV?
▼
Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $265.46 (-0.70%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 11.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IQV)Realized 20D OHLCV Swing Band: ±6.8%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY IQV SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (28% of score)
20D Institutional Volume Accumulation (±6.8% realized swing band)
▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (20% of score)
SEC XBRL FY 2025 (10-K): 11.8% FCF Margin ($1.92B FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)
Macro rate sensitivity & RSI-14 (55.7) create a -10 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$260.68+2.8% Next Q
56
Q2 (-2Q)Grade C$267.85+1.4% Next Q
59
Q3 (-1Q)Grade C$271.55-1.6% Next Q
61
CurrentGrade C$267.33+1.1% Hist 90D α
64
Trajectory: C (56) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the IQV Bull Thesis Could Fail
Even with a 64/100 (C) score, IQV faces multiple-compression risk if 33.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($266.69) or 200D SMA ($209.87) invalidates the momentum regime and cuts Target Base ($274.55) toward Bear Floor ($214.15).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IQV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IQV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IQV Stock dropped -2.81% Today — RQD Quant Desk Flash
IQVIA Holdings Inc. (IQV) dropped -2.81% to $267.33, trading at 87% of its 52-week range ($154.5 – $284.5). Solid steady margins (9% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 87% of its 52-week range ($154.5 – $284.5) with RSI-14 at 55.7 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.8% around $267.33 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $1.9B annual free cash flow.
Live IQV Headlines & Catalysts
MARKET WIREChartMill • 11h ago
IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical RatingsChartMill report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 14h ago
Iqvia Holdings Inc. Stock (IQV) - Quote NYSEmarketscreener.com report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 17h ago
Iqvia Holdings Stock Price Forecast. Should You Buy IQV?StockInvest.us report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 20h ago
IQVIA gains as R&D Solutions drive Q3 beatSeeking Alpha report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 23h ago
IQVIA Holdings Inc (IQV) Stock Up 3.5% but GF Value Says OvervalGuruFocus report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?Yahoo Finance report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
IQVIA (IQV) Stock Could Be Undervalued Following Its 55% RunSimply Wall St report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 3d ago
IQV Q3 deep dive: AI adoption and clinical momentum drive growth, guidance raisedClinical research company IQVIA (NYSE: IQV) reported Q3 2026 results topping the market’s revenue expectations, with sales up 8% year on year to $4.43 billion. The company expects the full year’s revenue to be around $17
CATALYSTYahoo • 3d ago
5 revealing analyst questions from IQVIA’s Q3 earnings callIQVIA delivered an 8% year-over-year revenue increase in Q3, with results that outpaced Wall Street expectations and prompted a positive market reaction. Management attributed this performance to accelerated growth in bo
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (IQV Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IQV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +66.11%🛡️ HOLDING TREND SUPPORT
2026-11-02O $279.0H $279.0L $267.3C $267.3VOL 1.43M
RES: $333.3SUP: $265.1SMA50: $266.7SMA200: $209.9
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IQV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.7%/yr Implied 5Y Growth
vs. +5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IQV today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IQV. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IQV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IQV)
Health Care Rank #132 of 1016
⚔️ INCY vs IQV Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IQV vs. INCY, MEDP, CRL, ICLR)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, IQVIA Holdings Inc. (IQV) ranks #132 by composite RQD confidence (64/100, grade C) and #43 by equity capitalization ($45.33B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 84/100 (A-) compared with IQV at 64/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IQV
ACTIVE
IQVIA Holdings Inc. | C | 64/100 | 33.3x | — | 9.4% | -2.81% | $45.33B | Benchmark Subject |
| INCY Incyte Corp. | A- | 84/100 | 18.4x | 92.8% | 42.4% | +3.07% | $23.68B | /incy-vs-iqv → |
| MEDP Medpace Holdings Inc. | B+ | 80/100 | 42.0x | — | 27.9% | -3.77% | $18.95B | /medp-vs-iqv → |
| CRL Charles River Laboratories International Inc. | C | 63/100 | — | — | 0.4% | -4.44% | $17.95B | /crl-vs-iqv → |
| ICLR ICON plc | B- | 71/100 | 71.9x | — | 3.1% | -1.91% | $16.50B | /iclr-vs-iqv → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001478242In its most recent audited fiscal period (FY2025, filed 2025-12-31), IQVIA Holdings Inc. (IQV) reported GAAP revenue of $16.31B (+5.9% vs. FY2024 revenue of $15.40B , and +8.8% cumulative change since FY2023) , GAAP net income of $1.36B, operating cash flow of $2.65B, and free cash flow of $1.92B (-5.1% YoY). On the balance sheet, IQV closed FY2025 with $29.94B in total assets against $13.88B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.31B | $1.36B | $2.65B | $1.92B | $29.94B | $13.88B |
| FY2024 (FY) | 2024-12-31 | $15.40B | $1.37B | $2.72B | $2.02B | $26.90B | $12.84B |
| FY2023 (FY) | 2023-12-31 | $14.98B | $1.36B | $2.15B | $1.47B | $24.93B | $5.83B |
3. IQV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, IQVIA Holdings Inc. (NYSE: IQV) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $267.33 (-2.81% 1D, market cap $45.33B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IQV ranks #132 in composite RQD confidence.
How does IQV compare to INCY and MEDP in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C (64/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A- grade (84/100 RQD, P/E 18.4x, ROIC 42.4%, cap $23.68B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IQV?
Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IQV trading relative to its 50-day, 200-day, and 52-week technical levels?
IQV last traded at $267.33 (-2.81% on volume of 1,150,295 shares), positioning the stock +0.24% above its 50-day simple moving average ($266.69) and +27.38% above its 200-day simple moving average ($209.87). Across its 52-week range of $154.50 to $284.50, IQV sits at the 86.8% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($249.15 to $285.51).
IQV Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IQV stock moving today?
Why IQV Stock dropped -2.81% Today — RQD Quant Desk Flash. Solid steady margins (9% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 64/100 (C)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IQV — IQVIA Holdings Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:11:27Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IQV scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." Across its five pillars: the Fundamental Cash Engine scores 13 of 20 (ROIC 9.4%; FCF yield 4.24%), suggesting cash generation that is adequate but not exceptional relative to the capital employed. Whale/13F Flow scores 18 of 20 (institutional accumulation and options positioning), the strongest pillar and a supportive signal for near-term demand. Insider Conviction scores 13 of 20 (SEC Form 4 and Congressional PTR cluster flow), a moderate reading. Macro Regime Fit scores 10 of 20 (Beta 1.16; sector sensitivity), indicating above-market sensitivity to broad moves. Forensic Balance Sheet scores 10 of 20 (Altman Z 2.22; Piotroski F 6/9; Debt/Equity 2.14), flagging leverage as the key constraint on the rating.
For a prospective investor, the picture is mixed: institutional positioning is a clear upside driver, while valuation (P/E TTM 33.3, EV/EBITDA 20.4) and elevated leverage limit margin for error. The rating frames the stock as balanced rather than compelling on fundamentals alone.
Snapshot
Business
IQVIA Holdings Inc. is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Commercial Physical & Biological Resarch industry. Per the profile, the company carries a market capitalization of $45.3B. Source data does not describe its specific products, customers, or revenue mechanics beyond sector and industry classification.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $16310.0M | $2182.0M | $1360.0M | N/A | $1920.0M | $1980.0M | $13884.0M |
| FY 2024 | $15405.0M | $2202.0M | $1373.0M | N/A | $2022.8M | $1702.0M | $12838.0M |
| FY 2023 | $14984.0M | $1977.0M | $1358.0M | N/A | $1474.7M | N/A | $5834.0M |
Revenue rose from $14984.0M (FY 2023) to $16310.0M (FY 2025), while net income was broadly flat across the three periods. Per the market data, the operating margin is 13.4%, the net margin 8.3%, and ROIC 9.4%. The Forensic Balance Sheet pillar cites an Altman Z-Score of 2.22 and a Piotroski F-Score of 6/9. Reported debt climbed from $5834.0M (FY 2023) to $13884.0M (FY 2025), and the source cites a Debt/Equity of 2.14.
Recent Catalysts & News Wire Analysis
- A "CATALYST"-tagged item (GREEN light) cites a Seeking Alpha headline: "IQVIA gains as R&D Solutions drive Q3 beat," the only non-yellow signal in the feed.
- A ChartMill item (YELLOW) references strong technical ratings and a possible breakout setup.
- A GuruFocus item (YELLOW) notes the stock was up 3.5% but that GF Value indicates overvaluation.
- Other wire items (Yahoo! Finance Canada, marketscreener.com, StockInvest.us) are general market-action and quote coverage.
- Per the market data, the stock closed at 275.06, down 1.43% on volume of 1,430,079.
- Butterfly Supply-Chain Graph: Not available in source data for supply-chain links; no butterfly links or proprietary signals are provided.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
The Butterfly Supply-Chain Graph lists supply chain as "NONE" with no butterfly links. Not available in source data for upstream or downstream dependencies, sector correlations, or second-order bottlenecks beyond the stated sector (Health Care) and industry classification.
Open Questions
- What specific products, customers, and revenue segments drive the reported revenue of $16310.0M?
- What explains the rise in reported debt from $5834.0M (FY 2023) to $13884.0M (FY 2025), and what are the maturity and interest terms?
- Why is EPS reported as N/A across all periods, and what is the reconciled per-share earnings history?
- What are the specific institutional and insider transactions underlying the Whale/13F and Insider Conviction pillar scores?
- What supply-chain dependencies and sector correlations apply, given the Butterfly graph is empty?
IQV Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for IQVIA Holdings Inc. (IQV) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 8h ago
IQVIA Holdings Inc. (IQV) Stock Price, News, Quote & History Yahoo! Finance Canada report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 11h ago
IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical Ratings ChartMill report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 14h ago
Iqvia Holdings Inc. Stock (IQV) - Quote NYSE marketscreener.com report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 17h ago
Iqvia Holdings Stock Price Forecast. Should You Buy IQV? StockInvest.us report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 20h ago
IQVIA gains as R&D Solutions drive Q3 beat Seeking Alpha report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 23h ago
IQVIA Holdings Inc (IQV) Stock Up 3.5% but GF Value Says Overval GuruFocus report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? Yahoo Finance report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
IQVIA (IQV) Stock Could Be Undervalued Following Its 55% Run Simply Wall St report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IQV Bull vs. Bear Conversation Board — What's Your Call at $267.33?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IQV 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $297.06 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IQV (C • RQD 64/100) a Buy at $275.06?
Welcome to the IQV (IQVIA Holdings Inc.) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (33.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $214.55 (-22.0%)
Spot @ $275.06 Pump the brakes on IQV — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IQV, but look at what you are paying: 33.3x trailing P/E with tightening sector spreads. Unless IQVIA Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $330.07 (+20.0%)
Spot @ $275.06 IQV cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IQV, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $275.06 (52-wk range $154.50 - $284.50), any beat on forward guidance forces shorts and underweight funds to chase.